AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10332518 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Adjustable Keyboard (kb1)
Number of subjects: 80
Study 10332518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7867175 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches applied for 12 hours daily for 30 days
Number of subjects: 0
Study 7867175 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches
Number of subjects: 0
Study 7867175 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin therapy
Number of subjects: 0
Study 7867175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1959368 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate (1 g every 6 hrs)
Number of subjects: 60
Study 1959368 — intervention group
Group type: COMPARATOR
Intervention: ranitidine (50 mg every 6 hrs)
Number of subjects: 60
Study 7124567 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamin B6 and magnesium
Number of subjects: 44
Study 30393015 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cig
Number of subjects: 263
Study 30393015 — intervention group
Group type: COMPARATOR
Intervention: cig‐sub
Number of subjects: 263
Study 28356136 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intermittent bolus with hypertonic saline
Number of subjects: 178
Study 28356136 — intervention group
Group type: COMPARATOR
Intervention: Slow continuous infusion with hypertonic saline
Number of subjects: 178
Study 27108405 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Number of subjects: 110
Study 27108405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Number of subjects: 110
Study 27108405 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 110
Study 24074637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (250-750 mg/day)
Number of subjects: 60
Study 24074637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22147202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 116
Study 22147202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 18973142 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed explanatory leaflet about urodynamic consultation
Number of subjects: 129
Study 18973142 — intervention group
Group type: COMPARATOR
Intervention: No detailed explanatory leaflet (control group)
Number of subjects: 129
Study 18022231 — intervention group
Group type: EXPERIMENTAL
Intervention: diacetylmorphine
Number of subjects: 8
Study 18022231 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 8
Study 15676176 — intervention group
Group type: COMPARATOR
Intervention: Obesity assessed by BMI (overweight and obese groups)
Number of subjects: 6676
Study 15676176 — intervention group
Group type: COMPARATOR
Intervention: WHR in the upper quartile
Number of subjects: 6676
Study 15676176 — intervention group
Group type: COMPARATOR
Intervention: Increasing WHR in women
Number of subjects: 6676
Study 12486207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested IFN‐alpha in type 1 diabetes
Number of subjects: 0
Study 12486207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested IFN‐alpha in rheumatoid arthritis
Number of subjects: 0
Study 12486207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested IFN‐alpha in multiple sclerosis (phase I trial)
Number of subjects: 0
Study 12486207 — intervention group
Group type: COMPARATOR
Intervention: Ingested IFN‐alpha (10,000 IU) in multiple sclerosis (phase II trial)
Number of subjects: 0
Study 9935129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of progestin (5 mg twice per week)
Number of subjects: 100
Study 9935129 — intervention group
Group type: COMPARATOR
Intervention: Continuous dosing of progestin (2.5 mg daily)
Number of subjects: 100
Study 9935129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (intermittent and continuous dosing)
Number of subjects: 100
Study 8527617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 276
Study 8527617 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 276
Study 2149829 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine (Group L)
Number of subjects: 100
Study 2149829 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 micrograms alfentanil (Group A)
Number of subjects: 100
Study 2149829 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms fentanyl (Group F)
Number of subjects: 100
Study 2149829 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms sufentanil (Group S)
Number of subjects: 100
Study 2149829 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms sufentanil without test dose (Group S‐)
Number of subjects: 100
Study 2149829 — intervention group
Group type: COMPARATOR
Intervention: Epidural narcotics (alfentanil, fentanyl, sufentanil)
Number of subjects: 100
Study 6987026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone (75 to 200 mg)
Number of subjects: 672
Study 6987026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone (100 to 150 mg)
Number of subjects: 672
Study 6987026 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (1,000 mg)
Number of subjects: 672
Study 6987026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 31707286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg of vitamin D supplementation
Number of subjects: 170
Study 31707286 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg of vitamin D supplementation
Number of subjects: 170
Study 31707286 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 μg of vitamin D)
Number of subjects: 170
Study 31707286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg and 25 μg of vitamin D supplementation
Number of subjects: 170
Study 31371396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ludwig staging system
Number of subjects: 106
Study 31371396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ishak staging system
Number of subjects: 106
Study 31371396 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological parameters (IFH and sinusoidal fibrosis)
Number of subjects: 106
Study 31371396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal fibrosis
Number of subjects: 106
Study 31371396 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Number of subjects: 106
Study 26175020 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation
Number of subjects: 100
Study 26175020 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilisation
Number of subjects: 100
Study 26175020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 25872789 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individualised aerobic exercise programme
Number of subjects: 60
Study 25872789 — intervention group
Group type: COMPARATOR
Intervention: 12-week waiting control group
Number of subjects: 60
Study 23498360 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated gaming technology training and audit tool
Number of subjects: 0
Study 21376910 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Restraint Fitting Stations
Number of subjects: 0
Study 21376910 — intervention group
Group type: COMPARATOR
Intervention: No use of Restraint Fitting Stations
Number of subjects: 0
Study 21376910 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of restraint ownership
Number of subjects: 0
Study 19681774 — intervention group
Group type: COMPARATOR
Intervention: Single stimulation (Group S)
Number of subjects: 60
Study 19681774 — intervention group
Group type: EXPERIMENTAL
Intervention: Double stimulation (Group D)
Number of subjects: 60
Study 17365952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea level (SL)
Number of subjects: 10
Study 17365952 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 m
Number of subjects: 10
Study 17365952 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 m
Number of subjects: 10
Study 14624940 — intervention group
Group type: EXPERIMENTAL
Intervention: High barley diet
Number of subjects: 10
Study 14624940 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 10
Study 11004042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Rhino (CBR)
Number of subjects: 50
Study 11004042 — intervention group
Group type: COMPARATOR
Intervention: Basic Ciaglia technique of percutaneous dilational tracheostomy (PDT)
Number of subjects: 50
Study 8971536 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil 5% (5‐FU) topical application plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Number of subjects: 505
Study 8971536 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization plus 5‐FU plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Number of subjects: 505
Study 8971536 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization plus 5‐FU
Number of subjects: 505
Study 1486776 — intervention group
Group type: EXPERIMENTAL
Intervention: Emcredil
Number of subjects: 40
Study 1486776 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 6365156 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of danazol
Number of subjects: 0
Study 6365156 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of danazol
Number of subjects: 0
Study 3086597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) followed by carmofur (HCFU) for more than three months (arm B)
Number of subjects: 173
Study 3086597 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) alone (arm A)
Number of subjects: 173
Study 28864036 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-targeted aerobic exercise training
Number of subjects: 126
Study 28864036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HR-targeted training)
Number of subjects: 126
Study 28295907 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of HF medication for 48 hours
Number of subjects: 20
Study 28295907 — intervention group
Group type: COMPARATOR
Intervention: Regular medication
Number of subjects: 20
Study 25764513 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of oral cholera vaccine at 14 day interval
Number of subjects: 356
Study 25764513 — intervention group
Group type: COMPARATOR
Intervention: Two doses of oral cholera vaccine at 28 day interval
Number of subjects: 356
Study 23724913 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg orally twice daily)
Number of subjects: 347
Study 23724913 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m² or docetaxel 75 mg/m² every 3 weeks)
Number of subjects: 347
Study 23724913 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 347
Study 23724913 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 347
Study 20578380 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated herbal moxibustion on Shenque (CV 8)
Number of subjects: 102
Study 20578380 — intervention group
Group type: COMPARATOR
Intervention: Western medication (analgesic)
Number of subjects: 102
Study 18400583 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intrauterine insemination
Number of subjects: 100
Study 18400583 — intervention group
Group type: COMPARATOR
Intervention: Double intrauterine insemination
Number of subjects: 100
Study 16618043 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point acupuncture
Number of subjects: 26
Study 16618043 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 26
Study 14762984 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary medicine intervention (specifics not provided)
Number of subjects: 429
Study 14762984 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician MD as complementary medicine practitioner
Number of subjects: 429
Study 14762984 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching complementary medicine in medical and nursing schools
Number of subjects: 429
Study 14762984 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about adverse reactions to complementary therapies
Number of subjects: 429
Study 14762984 — intervention group
Group type: EXPERIMENTAL
Intervention: Legalizing complementary medicine
Number of subjects: 429
Study 11000645 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (n = 137), starting at 10 mg/d and titrated to a maximum of 40 mg/d
Number of subjects: 415
Study 11000645 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment-primary care (PST-PC; n = 138)
Number of subjects: 415
Study 11000645 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (for dysthymia patients)
Number of subjects: 415
Study 11000645 — intervention group
Group type: COMPARATOR
Intervention: PST-PC (for dysthymia patients)
Number of subjects: 415
Study 11000645 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (for minor depression patients)
Number of subjects: 415
Study 11000645 — intervention group
Group type: COMPARATOR
Intervention: PST-PC (for minor depression patients)
Number of subjects: 415
Study 8792922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily (n = 29)
Number of subjects: 60
Study 8792922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 60
Study 1734739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 16
Study 1734739 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 16
Study 12267336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2gm WCMAS
Number of subjects: 74
Study 12267336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4gm WCMAS
Number of subjects: 74
Study 12267336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6gm WCMAS
Number of subjects: 74
Study 12267336 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hCG and progesterone levels
Number of subjects: 74
Study 12267336 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of 48 cases
Number of subjects: 74
Study 31090750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral digital impression (fully digital group)
Number of subjects: 20
Study 31090750 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression and scan model (conventional group)
Number of subjects: 20
Study 29096998 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3750846 SNP at the ARMS2/HTRA1 locus
Number of subjects: 1776
Study 29096998 — intervention group
Group type: EXPERIMENTAL
Intervention: rs10922109 SNP at the CFH locus
Number of subjects: 1776
Study 29096998 — intervention group
Group type: EXPERIMENTAL
Intervention: rs570618 SNP at the CFH locus
Number of subjects: 1776
Study 27068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellphone Assisted Remote Observation of Medication Adherence (CAROMA)
Number of subjects: 20
Study 27068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Active study medication
Number of subjects: 20
Study 27068252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25178925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 48
Study 22488460 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (usual outcall protocol of an academic hospital genetic risk program)
Number of subjects: 38
Study 22488460 — intervention group
Group type: COMPARATOR
Intervention: Model 2 (screening and referral procedures of a statewide toll-free phone line)
Number of subjects: 38
Study 22488460 — intervention group
Group type: COMPARATOR
Intervention: Model 2 (after 2 months follow-up)
Number of subjects: 38
Study 22488460 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (after 2 months follow-up)
Number of subjects: 38
Study 20102444 — intervention group
Group type: EXPERIMENTAL
Intervention: Local estrogen cream
Number of subjects: 75
Study 20102444 — intervention group
Group type: EXPERIMENTAL
Intervention: Local estrogen and testosterone cream
Number of subjects: 75
Study 20102444 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal lubricant KY gel (control)
Number of subjects: 75
Study 17914966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin monotherapy for 8 weeks followed by lactoferrin, interferon, and ribavirin for 24 weeks
Number of subjects: 111
Study 17914966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin, interferon, and ribavirin combination therapy
Number of subjects: 111
Study 17914966 — intervention group
Group type: COMPARATOR
Intervention: Interferon and ribavirin for 24 weeks
Number of subjects: 111
Study 15618068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior PCI
Number of subjects: 24166
Study 15618068 — intervention group
Group type: COMPARATOR
Intervention: No prior PCI
Number of subjects: 24166
Study 12355332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra-caffeine (Xenadrine(TM); XEN)
Number of subjects: 27
Study 12355332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 27
Study 10671656 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 0
Study 10671656 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 8853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (energy-restricted diet, physical exercise, intragastric balloon)
Number of subjects: 17
Study 8853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (58.4 kg) of those remaining or becoming acid refluxers
Number of subjects: 17
Study 8853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic gastric distension (500 ml balloon)
Number of subjects: 17
Study 1507022 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical procedures for analysis of data from periodontal research
Number of subjects: 0
Study 1507022 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II periodontal disease clinical trial
Number of subjects: 0
Study 2857088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 37
Study 2857088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31362548 — intervention group
Group type: EXPERIMENTAL
Intervention: K-wire fixation
Number of subjects: 448
Study 31362548 — intervention group
Group type: COMPARATOR
Intervention: Locking-plate fixation
Number of subjects: 448
Study 30021340 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 100
Study 30021340 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 27149465 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 session per week for 3 weeks
Number of subjects: 60
Study 27149465 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 single session
Number of subjects: 60
Study 27149465 — intervention group
Group type: COMPARATOR
Intervention: Sham rESWT - 1 session per week for 3 weeks
Number of subjects: 60
Study 27149465 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3 sessions
Number of subjects: 60
Study 24806009 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition
Number of subjects: 43
Study 24806009 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis with plate and screws
Number of subjects: 43
Study 22239911 — intervention group
Group type: EXPERIMENTAL
Intervention: GO intervention group
Number of subjects: 35
Study 22239911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 35
Study 20040123 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 18474343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carvedilol coupled with nurse management
Number of subjects: 64
Study 18474343 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 15673897 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cm H(2)O) applied during induction of anesthesia
Number of subjects: 30
Study 15673897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no continuous positive airway pressure or PEEP)
Number of subjects: 30
Study 12757986 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management and relaxation-training program (group-education 2 h a week for 14 weeks)
Number of subjects: 31
Study 12757986 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the program later)
Number of subjects: 31
Study 12757986 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management and relaxation-training program
Number of subjects: 31
Study 12757986 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 10081996 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative enteral nutrition (fed group)
Number of subjects: 19
Study 10081996 — intervention group
Group type: EXPERIMENTAL
Intervention: IV crystalloid (nonfed group)
Number of subjects: 19
Study 10081996 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonoperative volunteers)
Number of subjects: 19
Study 7751427 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of sustained-release verapamil in fed subjects
Number of subjects: 0
Study 7751427 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of sustained-release verapamil in fed subjects
Number of subjects: 0
Study 7751427 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of sustained-release verapamil in fed subjects (rapid absorbers)
Number of subjects: 0
Study 2089973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Amphotericin B (2 g/day)
Number of subjects: 51
Study 2089973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7443592 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 2
Study 7443592 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin with Intralipid
Number of subjects: 2
Study 7443592 — intervention group
Group type: COMPARATOR
Intervention: Control (Heparin without Intralipid)
Number of subjects: 2